C. Russell Trenary III has been at the helm of Outlook Therapeutics, Inc. as the President and CEO since July 2021. With decades of leadership in the medical devices field, he previously led InnFocus, a glaucoma medical device company, until...
C. Russell Trenary III has been at the helm of Outlook Therapeutics, Inc. as the President and CEO since July 2021. With decades of leadership in the medical devices field, he previously led InnFocus, a glaucoma medical device company, until its sale to Santen Pharmaceutical in 2020. He has also served as CEO for other companies focused on eye care and orthodontics. At Outlook Therapeutics, Trenary received a significant stock option grant of 4 million shares upon joining, which was tied to his performance and the company’s success. His compensation strategy is simple: a base salary of $600,000 plus potential bonuses tied to specific company performance goals. Despite a big year in 2021, his total earnings saw a drop in 2023, which reflects the company's evolving performance. C. Russell is not just an executive; he’s an insider with a depth of experience that drives the company’s vision forward. His expertise positions him as a key player in shaping Outlook’s innovative approach to medical solutions.